4.8 Article

Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML

Related references

Note: Only part of the references are listed.
Article Multidisciplinary Sciences

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

Jiong Hu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Article Chemistry, Multidisciplinary

Monomethylarsenite competes with Zn2+ for binding sites in the glucocorticoid receptor

Anne M. Spuches et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)

Article Multidisciplinary Sciences

PML targeting eradicates quiescent leukaemia-initiating cells

Keisuke Ito et al.

NATURE (2008)

Article Cell Biology

Arsenic degrades PML or PML - RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway

Valerie Lallemand-Breitenbach et al.

NATURE CELL BIOLOGY (2008)

Article Biochemistry & Molecular Biology

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Rihab Nasr et al.

NATURE MEDICINE (2008)

Article Oncology

Identification of arsenic-binding proteins in human breast cancer cells

Xinyan Zhang et al.

CANCER LETTERS (2007)

Article Multidisciplinary Sciences

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

Jun Lu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Review Biology

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy

Guang-Biao Zhou et al.

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2007)

Review Biochemistry & Molecular Biology

PML protein isoforms and the RBCC/TRIM motif

K Jensen et al.

ONCOGENE (2001)